Celularity (CELU) Competitors

$0.78 -0.10 (-11.24%)

As of 12:55 PM Eastern

CELU vs. CUE, BMEA, AIFC, KALA, and ONCY

Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Cue Biopharma (CUE), Biomea Fusion (BMEA), ALT5 Sigma (AIFC), KALA BIO (KALA), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does Celularity compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Cue Biopharma has a net margin of -96.85% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-96.85%	-165.19%	-77.77%
Celularity	-345.45%	N/A	-77.94%

Cue Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 1.8% of Cue Biopharma shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cue Biopharma had 3 more articles in the media than Celularity. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for Celularity. Cue Biopharma's average media sentiment score of 0.51 beat Celularity's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cue Biopharma has higher revenue and earnings than Celularity. Cue Biopharma is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.57	-$26.60M	-$9.61	N/A
Celularity	$26.55M	0.85	-$91.72M	-$3.33	N/A

Celularity has a consensus price target of $6.00, suggesting a potential upside of 668.25%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cue Biopharma beats Celularity on 9 of the 16 factors compared between the two stocks.

How does Celularity compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Biomea Fusion has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-305.60%	-128.09%
Celularity	-345.45%	N/A	-77.94%

Biomea Fusion has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 18.4% of Biomea Fusion shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Biomea Fusion had 5 more articles in the media than Celularity. MarketBeat recorded 6 mentions for Biomea Fusion and 1 mentions for Celularity. Biomea Fusion's average media sentiment score of 0.37 beat Celularity's score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biomea Fusion has higher earnings, but lower revenue than Celularity. Biomea Fusion is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$1.31	N/A
Celularity	$26.55M	0.85	-$91.72M	-$3.33	N/A

Biomea Fusion presently has a consensus price target of $8.29, indicating a potential upside of 429.44%. Celularity has a consensus price target of $6.00, indicating a potential upside of 668.25%. Given Celularity's higher probable upside, analysts clearly believe Celularity is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biomea Fusion beats Celularity on 10 of the 16 factors compared between the two stocks.

How does Celularity compare to ALT5 Sigma?

Celularity (NASDAQ:CELU) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Celularity has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.85	-$91.72M	-$3.33	N/A
ALT5 Sigma	$24.84M	4.83	-$344.51M	N/A	N/A

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 668.25%. Given Celularity's stronger consensus rating and higher possible upside, equities analysts clearly believe Celularity is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Celularity has a net margin of -345.45% compared to ALT5 Sigma's net margin of -1,386.90%. Celularity's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
ALT5 Sigma	-1,386.90%	-50.52%	-45.05%

Celularity has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

In the previous week, ALT5 Sigma had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for ALT5 Sigma and 1 mentions for Celularity. ALT5 Sigma's average media sentiment score of 0.97 beat Celularity's score of 0.00 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celularity beats ALT5 Sigma on 9 of the 14 factors compared between the two stocks.

How does Celularity compare to KALA BIO?

Celularity (NASDAQ:CELU) and KALA BIO (NASDAQ:KALA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

KALA BIO has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
KALA BIO	N/A	-12,971.16%	-90.83%

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 668.25%. KALA BIO has a consensus price target of $1,018.75, indicating a potential upside of 29,566.57%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

19.0% of Celularity shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Celularity has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.23, indicating that its share price is 323% less volatile than the S&P 500.

KALA BIO has lower revenue, but higher earnings than Celularity. KALA BIO is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.85	-$91.72M	-$3.33	N/A
KALA BIO	N/A	N/A	-$26.98M	-$3.33	N/A

In the previous week, KALA BIO had 4 more articles in the media than Celularity. MarketBeat recorded 5 mentions for KALA BIO and 1 mentions for Celularity. Celularity's average media sentiment score of 0.00 beat KALA BIO's score of -0.37 indicating that Celularity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KALA BIO	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Celularity beats KALA BIO on 7 of the 12 factors compared between the two stocks.

How does Celularity compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Oncolytics Biotech has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-243.94%
Celularity	-345.45%	N/A	-77.94%

Oncolytics Biotech currently has a consensus price target of $8.50, indicating a potential upside of 853.98%. Celularity has a consensus price target of $6.00, indicating a potential upside of 668.25%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Oncolytics Biotech is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oncolytics Biotech has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

Oncolytics Biotech has higher earnings, but lower revenue than Celularity. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.29	N/A
Celularity	$26.55M	0.85	-$91.72M	-$3.33	N/A

In the previous week, Oncolytics Biotech had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for Oncolytics Biotech and 1 mentions for Celularity. Oncolytics Biotech's average media sentiment score of 0.00 equaled Celularity'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oncolytics Biotech beats Celularity on 9 of the 15 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.61M	$3.39B	$6.21B	$12.32B
Dividend Yield	N/A	2.25%	2.78%	5.22%
P/E Ratio	-0.23	15.26	20.74	25.72
Price / Sales	0.85	310.90	559.82	77.90
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	-0.59	7.05	9.82	6.79
Net Income	-$91.72M	$24.11M	$3.55B	$333.43M
7 Day Performance	N/A	N/A	N/A	0.49%
1 Month Performance	-38.50%	5.91%	6.79%	9.28%
1 Year Performance	-53.23%	80.50%	42.86%	42.99%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	1.2423 of 5 stars	$0.78 -11.2%	$6.00 +668.2%	-47.3%	$22.61M	$26.55M	N/A	220
CUE Cue Biopharma	0.2598 of 5 stars	$33.39 +11.9%	N/A	-95.0%	$109.04M	$27.47M	N/A	60	Analyst Upgrade Gap Down
BMEA Biomea Fusion	2.4652 of 5 stars	$1.51 +1.7%	$9.50 +531.2%	-5.4%	$108.81M	N/A	N/A	50	Gap Up
AIFC ALT5 Sigma	0.4426 of 5 stars	$0.84 +0.1%	N/A	-83.8%	$106.21M	$24.84M	N/A	170
KALA KALA BIO	1.9198 of 5 stars	$0.12 +7.4%	$20.38 +17,464.7%	-100.0%	$105.96M	N/A	N/A	30	Stock Split Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. CUE, BMEA, AIFC, KALA, and ONCY

How does Celularity compare to Cue Biopharma?

Summary

How does Celularity compare to Biomea Fusion?

Summary

How does Celularity compare to ALT5 Sigma?

Summary

How does Celularity compare to KALA BIO?

Summary

How does Celularity compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. CUE, BMEA, AIFC, KALA, and ONCY

How does Celularity compare to Cue Biopharma?

Is CUE or CELU more profitable?

Which has more volatility and risk, CUE or CELU?

Do institutionals & insiders believe in CUE or CELU?

Does the media refer more to CUE or CELU?

Which has preferable earnings & valuation, CUE or CELU?

Do analysts prefer CUE or CELU?

Summary

How does Celularity compare to Biomea Fusion?

Is BMEA or CELU more profitable?

Which has more volatility & risk, BMEA or CELU?

Do insiders and institutionals believe in BMEA or CELU?

Does the media refer more to BMEA or CELU?

Which has better earnings and valuation, BMEA or CELU?

Do analysts prefer BMEA or CELU?

Summary

How does Celularity compare to ALT5 Sigma?

Do institutionals and insiders believe in CELU or AIFC?

Which has preferable valuation & earnings, CELU or AIFC?

Do analysts prefer CELU or AIFC?

Is CELU or AIFC more profitable?

Which has more risk & volatility, CELU or AIFC?

Does the media prefer CELU or AIFC?

Summary

How does Celularity compare to KALA BIO?

Is CELU or KALA more profitable?

Do analysts prefer CELU or KALA?

Do institutionals and insiders believe in CELU or KALA?

Which has more risk & volatility, CELU or KALA?

Which has preferable valuation & earnings, CELU or KALA?

Does the media prefer CELU or KALA?

Summary

How does Celularity compare to Oncolytics Biotech?

Is ONCY or CELU more profitable?

Do analysts recommend ONCY or CELU?

Do insiders & institutionals have more ownership in ONCY or CELU?

Which has more volatility & risk, ONCY or CELU?

Which has preferable valuation & earnings, ONCY or CELU?

Does the media favor ONCY or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools